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Abstract: Antibodies are one of the most promising components of the biotechnology reper-
toire for the purpose of drug delivery. On the one hand, they are proven agents for cell-se-
lective delivery of highly toxic agents in a small but expanding number of cases. This tech-
nology calls for the covalent attachment of the cytotoxin to a tumor-specific antibody by a
linkage that is reversible under appropriate conditions (antibody conjugate therapy, ACT—
“passive delivery”). On the other hand, the linker cleavage can be accomplished by a protein
catalyst attached to the tumor-specific antibody (“catalytic delivery”). Where the catalyst is
an enzyme, this approach is known as antibody-directed enzyme prodrug therapy (ADEPT).
Where the transformation is brought about by a catalytic antibody, it has been termed anti-
body-directed abzyme prodrug therapy (ADAPT). These approaches will be illustrated with
emphasis on how their demand for new biotechnology is being realized by structure-based
protein engineering. 
INTRODUCTION
The origin of the “magic bullet” concept of selective delivery of a cytotoxic
agent to tumor cells originates from the imagination of Paul Ehrlich (left
inset) (Nobel Laureate, 1908). His concept arose from the experience of
19th century German chemists who selectively stained tissues for histologi-
cal examination. Ehrlich argued that if a compound could be made that se-
lectively targeted a disease-causing organism, then a toxin for that organism
could be delivered along with the agent of selectivity. Hence, a “magic bul-
let” would be created that killed only the organism targeted [1]. For many
years, the sought-for means of delivery was thought to lie in cell-selective
dyestuffs. However, a completely new approach was created by the discov-
ery of monoclonal antibodies by Cesar Milstein and Georges Köhler (Nobel
Prize, 1984) [2]. In particular, Milstein demonstrated that spleen cells from
mice immunized with rat thymocyte membranes and fused with a mouse
myeloma led to hybridomas with the specific ability to detect different, pre-
viously undefined antigens on different subpopulations of lymphoid cells. Some of these hybrids were
selected and screened for the production of antibodies to rat thymocytes by a binding assay.
*Lecture presented at the Polish–Austrian–German–Hungarian–Italian Joint Meeting on Medicinal Chemistry, Kraków, Poland,
15–18 October 2003. Other presentations are published in this issue, pp. 907–1032.
‡Corresponding author 
Paul Ehrlich
Between 5000 and 36 000 antibody molecules per cell could be bound
at saturation to different cell markers on the thymocytes. The method is
therefore extremely sensitive and permits selective identification down to
minor membrane molecules and also of antigens on small subpopulations of
a heterogeneous mixture of cells [3]. 
In the almost three decades since the development of these methods for
preparing monoclonal antibodies, we are finally beginning to see their fruits
for cancer therapy [4]. Early ideas were that “naked” tumor-specific anti-
bodies might lead to cell clearance directly. Later work sought to use tumor-
specific antibodies to deliver radioactive isotopes (e.g., I131) to cause selec-
tive tumor cell killing by localized high-energy radioactive emission. More
success has attended work on two aspects of antibody delivery of cytotoxic
agents.
In antibody-directed therapy (ADT), the toxin is covalently bonded to the antibody to be released
after reaching the target tumor cell. From a large number of toxins explored, one product has gained
FDA approval. Work originating in Seattle focused on the treatment of acute myeloid leukemia (AML)
with antibodies specific for a CD33 cell surface marker that is characteristic in some 20 % of AML
cases. AML is the most common type of acute leukemia in adults. Although conventional chemother-
apy induces clinical remissions in most patients with AML, recurrent leukemia represents the major ob-
stacle to cure. Chemotherapy specifically targeted to leukemic cells by monoclonal antibodies might en-
able patients to achieve remissions more safely than using conventional approaches. After evaluating a
series of phase II studies, the U.S. Food and Drug Administration approved Mylotarg™ (gemtuzumab
ozogamicin) for the treatment of patients with CD33-positive AML in first relapse who are 60 years or
older and who are not considered candidates for other types of cytotoxic chemotherapy. Mylotarg has
been jointly developed and launched by Celltech Group and the Wyeth-Ayerst Research division of
American Home Products as a treatment for AML. Possible first-line therapy could follow depending
on further studies, creating a potential market of USD 300 million.
Gemtuzumab ozogamicin, GO, is a bioconjugate of a humanized anti-CD33 antibody with the
ene-diyne calicheamicin γ1. Calicheamicin (Fig. 1) is a minor DNA groove-binder that causes double-
stranded DNA breaks and apoptosis of the target cells, and is too dangerously toxic for direct clinical
use. However, the GO bioconjugate selectively targets CD33 markers, internalizes into the AML cells,
and releases calicheamicin to penetrate the nucleus and there cause unrepairable DNA damage leading
to apoptosis (Fig. 1). 
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Fig. 1 Calicheamicin is activated by cleavage of the S–S bond. The released thiol adds to the α,β-unsaturated ketone
bringing about a conformational change which enables the Bergman rearrangement. This generated the benzene-
1,4-diradical that abstracts two hydrogen atoms from proximate residues in DNA causing a double-strand break.
The second use of antibody delivery involves the catalyzed production of the toxic agent at the
tumor site by transformation of an inactive prodrug. Such antibody-directed enzyme prodrug therapy
(ADEPT) was conceived by Ken Bagshawe [6] and has been developed in many laboratories, particu-
larly in Astra-Zeneca UK. His ADEPT approach consists of three stages: administration of an antibody-
enzyme conjugate; subsequent administration of a clearing antibody to eliminate unbound antibody
conjugate from the periphery; and administration of prodrug 2–3 d after the conjugate. Zeneca has fo-
cused on a conjugate of a bacterial carboxypeptidase CPG2 to an antibody raised to a colorectal tumor
cell marker. The preferred prodrug was a benzoic acid mustard linked as an amide to L-glutamic acid
(Fig. 2). Hydrolysis of the amide by CPG2 released the mustard with an increase in activity of some
15-fold. This process proved able to kill human LS147T colorectal tumor xenografts in mice using an
ADEPT regimen [7] (Fig. 2).
RESULTS
ADEPT has limitations, and these include the response of the patient’s immune system to the two pro-
teins: the tumor-specific fragment antibody and the bacterial carboxypeptidase. In one approach to re-
solving these problems, we sought to generate a human (or humanized) catalytic antibody capable of
converting a prodrug into the cytotoxic agent. However, catalytic antibodies have to date proved inef-
fective at cleaving unactivated amides, such as the Zeneca prodrug 4-[(2-chloroethyl),(2-mesyl-
oxyethyl)-amino]-benzoyl-L-glutamic acid (Fig. 2). We therefore elected to generate a carbamatase
antibody that could operate on a carbamate prodrug (Fig. 3). We named the resulting process “ADAPT”,
being antibody-directed abzyme prodrug therapy [8].
© 2004 IUPAC, Pure and Applied Chemistry 76, 983–989
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Fig. 2 Conversion of a benzoic acid glutamate amide prodrug into an active benzoic acid mustard by
carboxypeptidase CPG2.
Fig. 3 (a) Carbamate prodrug and its conversion via a BAc2 mechanism into the phenolic mustard; (b) transition-
state analog.
We proposed to enhance the disfavored BAc2 mechanism of carbamate cleavage, which is nor-
mally some two decades slower than the favored E1cb mechanism simply through consideration of the
problems of generating a stable transition-state analog (TSA) for the latter process. Paul Wentworth de-
signed and synthesized a phosphonamide TSA for prodrug cleavage (Fig. 3), used it to immunize BalbC
mice, and raised a large number of monoclonal antibodies with good binding affinity for the TSA.
Several of these antibodies proved capable of effective hydrolysis of the carbamate linkage in 4-nitro-
phenyloxycarbonylaminoisophthalate, while others showed significant cell-kill activity for treatment of
human LoVo cells in tissue culture. Disappointingly, there was no direct correlation between such ac-
tivity and the results of a cell-kill assay in vitro [8]. Nonetheless, a mechanistic analysis of selected cat-
alytic antibodies established that, as scheduled, they promoted the disfavored BAc2 mechanism by some
6–7 decades relative to the uncatalyzed reaction rate. DF8D5 thus emerged as one of the most effective
catalytic antibodies generated in the mid-1990s [10]. However, its performance (as IgG or Fab) was still
two slow for in vivo development, and the general Km of such abzymes for the prodrug was on the high
side for potential therapeutic use. 
We therefore sought improvements within the manifold of production of catalytic antibodies
using murine immunization with TSAs but with very limited success. It became apparent that our task
called for new chemistry and a new biotechnology. In particular, the use of the mouse as a source of
monoclonal antibodies had proved too uncertain in our hands and in the hands of others, in addition to
being a time-consuming and expensive approach to the task.
The whole process of finding catalytic antibodies among the murine immunoglobulin repertoire
by screening for turnover has to be one of the most inefficient processes imaginable. It has been brought
into limited viability by reducing the size of the protein repertoire from some 10 million candidates to
a few hundred by selective induction of their production using stable transition-state analogs a im-
munogens. That process itself relies on the insights of Linus Pauling [11] and Bill Jencks [12] and is
based on the expectation that a protein that has high affinity for a TSA will be a catalyst for the re-
spective reaction. While this remains a strong principle of how enzymes work, it has not proved to be
strongly validated by an analysis [13] of the performance of catalytic antibodies using the simple, de-
rived relationship:
log kcat – log kuncat = log Km – log Ki.
We therefore reconsidered the basic requirements for identification and production of a protein
catalyst and came up with the following specifications:
• access to much larger protein libraries, not necessarily of immunoglobulin proteins;
• employment of selection rather than screening processes to identify catalysts;
• selection for turnover rather than for affinity; and
• deployment of chemistry whose masked reactivity is inherently incompatible with cell viability.
We had in fact been close to some of these objectives in work in the early 1980s when we sought
unsuccessfully to find esterase antibodies using as immunogen an aryl-trifluoromethylketone based on
an irreversible inhibitor of acetylcholine esterase [14]. The concept returned, stimulated by sequential
studies of Serge Halazy [15] and Kim Janda [16]. We chose to apply it to the difficult task of generat-
ing a catalytic antibody for an aryl phosphatase process, aware that Steve Withers had demonstrated the
suicidal potential of p-difluoromethylphenyl phosphate for a tyrosine phosphatase [17]. Accordingly,
we first designed and synthesized the suicide inhibitor needed for the turnover selection process
(Fig. 4). In line with the work of Withers [17], this agent proved to be an irreversible inhibitor for al-
kaline phosphatase since phosphate hydrolysis generated an o-difluoromethylphenol which, on sponta-
neous elimination of fluoride, was converted into a suicidal quinone methide. The key feature of this
essential control is that the alkaline phosphatase became irreversibly inactivated after several turnovers
of the substrate [18]. Moreover, the whole process could be monitored in real time using surface plas-
mon resonance.
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We then turned to the need for a new biotechnology and engaged the wholly synthetic HuCAL
fragment antibody library from Morphsys, which has 2 billion independent members from the IgG fam-
ily of proteins [19]. Because this library can be accessed on the surface of a phagemid vector, the sui-
cidal activity of the quinone methide (generated following phosphate hydrolysis) can be tolerated. It
goes without saying that no mouse could withstand such an insult! The deployment of the suicide sub-
strate (Fig. 4) as a selection reagent for the HuCAL library was immediately successful. After only two
rounds of panning, several hundred candidate phages were identified capable of turnover of the suicide
substrate with Km in the range 10
–2 to 10–6 M. A small selection of these was monitored by surface
plasmon resonance in real time to identify the most efficient candidate by its immobilization to the gold
surface and scFv TT1 was chosen for detailed analysis. 
This single-chain protein is capable of turnover of p-nitrophenyl phosphate, PNPP, with an en-
hancement over the spontaneous rate (kcat/kuncat) of 2.3 × 105. With a Km of 46 µM, this corresponds
to a catalytic proficiency of 5 × 109 M–1, making it one of the most proficient catalytic antibodies yet
described [20], and 100 times superior to the best antibody screened from a hybridoma system [21].
Because the selection process is innocent of any particular mechanism for the phosphate hydrolysis
process, we established that TT1 has a broad pH optimum in the range pH 5–9, that it has no metal ion
requirement, and that it is inhibited by vanadate at 10–6 M. It is possible to tease out some information
on the mechanism by site-directed mutagenesis of the modeled binding site for aryl phosphate sub-
strates. This identified the residues Thr-H135 and Ser-H136 as being essential for catalysis while mu-
tation of Lys-H113, Tyr-H133, and Asp-H137 to Ala had little effect on the kinetics of cleavage.
With confidence derived from these results, we sought to improve the performance of TT1 by
evolution through random mutagenesis of the whole structure with error-prone PCR. Aiming at a target
of some 15 mutations per scFv chain, after 3 rounds of panning we identified 10 candidates, which
proved to contain 3 copies of TT1.D1 and 2 copies of TT1.D2. These had 13 and 16 mutations respec-
tively, distributed throughout the sequence. Both show one decade improvement in their hydrolysis of
PNPP, largely through enhanced kcat. It remains for future work to devise a strategy for directed evolu-
tion to enhance affinity of the scFvs for substrate [20].
© 2004 IUPAC, Pure and Applied Chemistry 76, 983–989
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Fig. 4 Suicide substrates for alkaline phosphatase. Steps: (a) phosphate ester hydrolysis with release of phosphate;
(b) loss of fluoride generates a giunone methide; (c) capture of an enzymic nucleophile in the active site binds the
catalyst to the surface and inactivatives it.
CONCLUSION
This enterprise is the first example of the start-to-finish use of a man-made protein library to deliver an
efficient catalyst by selection for turnover. The rates of turnover achieved match those required for con-
version of a prodrug into a cytotoxic agent in vivo. Moreover, as the library has been constructed on the
human immunoglobulin scaffold, it can be expected to be only weakly immunogenic in clinical appli-
cation. It therefore represents the most promising approach to the ADAPT concept and the delivery of
Ehrlich’s “Magic Bullet” on an antibody scaffold.
ACKNOWLEDGMENTS
We thank the BBSRC for financial support (Studentship to J.H.R and Grant 50B/07047 to support
A.M.); the EC for a Network Grant (ERBFMRXCT98-0193, studentships to S.C-T. and D.L.); and to
MorphoSys AG for their constructive collaboration on HuCAL.
REFERENCES
1. P. Ehrlich. Lancet 172, 1634 (1907). 
2. C. Milstein. Angew. Chem. 97, 819–828 (1985); G. Kohler, “Derivation and diversification of
monoclonal antibodies,” (Nobel Lecture), Biosci. Rep. 5, 533–549 (1985).
3. A. F. Williams, G. Galfre, C. Milstein. Cell 12, 663–673 (1977).
G. M. BLACKBURN et al.
© 2004 IUPAC, Pure and Applied Chemistry 76, 983–989
988
Fig. 5 Selection for turnover. (i) Catalytic antibody on phage surface binds and cleaves phosphate substrate; (ii)
phenolic product loses fluoride forming a quinine methide; (iii) quinine methide bonds covalently to nucleophile
(X) in/near active site of antibody; (iv) after washing away nonreactive phage, disulfide bond is cleaved by
dithiothreitol to release phage from surface; (v) selected phage cloned and amplified; (vi) phage used to reenter
panning cycle for refinement of catalyst selection.
4. Reviewed by I. Bernstein, “Antibody-delivered Therapy”, Leukaemia Conference, 1–2 February,
<http://www.webtie.org/sots/Meetings/Leukemia/02-2000/transcripts/bernstein/Transcript.htm>.
5. I. Niculescu-Duvaz. Curr. Opin. Mol. Ther. 2, 691–696 (2000); E. L. Sievers. Blood Cells,
Molecules, Diseases 31, 7–10 (2003); D. L. Meyer and P. D. Senter. Annu. Rep. Med. Chem. 38,
229–237 (2003). 
6. K. D. Bagshawe. Third Gordon Hamilton-Fairley Memorial Lecture, “Tumour markers—where
do we go from here?” Brit. J. Cancer 48, 167 (1983). Idem, Tumor Targeting in Cancer Therapy,
pp. 321–326 (2002).
7. D. C. Blakey, B. E. Valcaccia, S. East, A. F. Wright, F. T. Boyle, C. J. Springer, P. J. Burke, R. G.
Melton, K. D. Bagshawe. Cell Biophys. 22, 1–8 (1993). 
8. In the event, Astra-Zeneca subsequently chose to develop a carbamate prodrug for their ADEPT
program as this gave a much higher enhancement of toxicity on carbamatase cleavage by CPG2.
R. I. Dowell, C. J. Springer, D. H. Davies, E. M. Hadley, P. J. Burke, F. T. Boyle, FR. G. Melton,
T. A. Connors, D. C. Blakey, A. B. Mauger. J. Med. Chem. 39, 1100–1105 (1996).
9. P. Wentworth, A. Datta, D. Blakey, T. Boyle, L. J. Partridge, G. M. Blackburn. Proc. Natl. Acad.
Sci. USA 93, 799–803 (1996).
10. P. Wentworth, A. Datta, S. Smith, A. Marshall, L. J. Partridge, G. M. Blackburn. J. Am. Chem.
Soc. 119, 2315–2316 (1997).
11. L. Pauling. Chem. Eng. News 24, 1375–1377 (1946).
12. W. P. Jencks. Catalysis in Chemistry and Enzymology, p. 288, McGraw-Hill, New York (1968).
13. J. W. Jacobs. Biotechnology 9, 258–262 (1991); J. D. Stewart and S. J. Benkovic. Nature
(London) 375, 388–391 (1995).
14. G. M. Blackburn and D. R. Burton. Unpublished observations.
15. S. Halazy, V. Berges, A. Ehrhard, C. Danzin. Bioorg. Chem. 18, 330–344 (1990).
16. K. D. Janda, L.-C. Lo, L. Chih-Hung, M.-M. Sim, R. Wang, C.-H. Wong, R. A. Lerner. Science
(Washington, DC) 275, 945–948 (1997).
17. Q. Wang, U. Dechert, F. Jirik, S. G. Withers. Biochem. Biophys. Res. Commun. 200, 577–583
(1994). 
18. J. R. Betley, S. Cesaro-Tadic, A. Mekhalfia, J. H. Rickard, H. Denham, L. J. Partridge, A.
Plückthun, G. M. Blackburn. Angew. Chem., Int. Ed. 41, 775–777 (2002).
19. A. Knappik, L. Ge, A. Honegger, P. Pack, M. Fischer, G. Wellnhofer, A. Hoess, J. Wolle, A.
Pluckthun, B. Virnekas. J. Mol. Biol. 296, 57–86 (2000).
20. S. Cesaro-Tadic, D. Lagos, A. Honegger, J. H. Rickard, A. Mekhalfia, L. J. Partridge, G. M.
Blackburn, A. Plückthun. Nature Biotechnol. 21, 679–685 (2003).
21. T. S. Scanlan, J. R. Prudent, P. G. Schultz. J. Am. Chem. Soc. 113, 9397–9398 (1991).
© 2004 IUPAC, Pure and Applied Chemistry 76, 983–989
Passive and catalytic antibodies and drug delivery 989
